AMG 487 is primarily used in research settings for its potent antagonistic activity against the chemokine receptors CCR6 and CCR8. It has been investigated for its potential to modulate immune responses, particularly in the context of inflammatory and autoimmune diseases. By blocking these receptors, AMG 487 can inhibit the migration of specific T-cell subsets involved in inflammation, making it a valuable tool compound in studies related to conditions such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. Its selectivity helps researchers dissect the role of CCR6 and CCR8 signaling pathways in immune cell recruitment and disease progression. While not developed for clinical use, AMG 487 supports the discovery and validation of therapeutic targets in immunology.